Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: gMG Clear all
Recruiting Phase 3 Interventional

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Placebo, Cladribine Low Dose, Cladribine High Dose
Other · Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
21
States / cities
Phoenix, Arizona • Longmont, Colorado • Farmington, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 15, 2026, 7:23 AM EDT
Recruiting Phase 3 Interventional

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

NCT06607627
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Gefurulimab
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 15, 2026, 7:23 AM EDT
Recruiting Phase 3 Interventional

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Telitacicept, Placebo
Biological · Drug
Lead sponsor
Vor Biopharma
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 15, 2026, 7:23 AM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

NCT06909214
View directory record Official record
Conditions
New Onset Generalized Myasthenia Gravis (gMG)
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
La Jolla, California • Rancho Mirage, California • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 15, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

NCT06471361
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
New Haven, Connecticut • Tampa, Florida • Columbia, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 15, 2026, 7:23 AM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
ALXN1720, Placebo
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Orange, California • Fort Collins, Colorado • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 15, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

NCT05681715
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Orange, California • San Francisco, California • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 15, 2026, 7:23 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
Interventions
Efgartigimod IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Fresno, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 15, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

NCT02301624
View directory record Official record
Conditions
Refractory Generalized Myasthenia Gravis
Interventions
Eculizumab, Placebo
Biological · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 15, 2026, 7:23 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201
View directory record Official record
Conditions
Multiple Sclerosis, Myasthenia Gravis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 15, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

NCT00727194
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 15, 2026, 7:23 AM EDT
Not yet recruiting No phase listed Observational

Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG

NCT07226830
View directory record Official record
Conditions
Myasthenia Gravis Generalized
Interventions
Not listed
Lead sponsor
BioSensics
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 15, 2026, 7:23 AM EDT
Recruiting No phase listed Observational

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

NCT06312644
View directory record Official record
Conditions
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Interventions
Ultomiris
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 15, 2026, 7:23 AM EDT